Only the National Health Insurance Service left to go, the ultra-high-priced novel CAR-T therapy ‘Kymriah (tisagenlecleucel)’ passed all the steps necessary for insurance benefit.

In other words, the fate of Kymriah’s reimbursement now lies

The fate of Kymriah’s reimbursement, a drug that costs around ₩500 million for a single shot, now lay at the hand of the NHIS negotiations. However, the prevailing view is that the road to reimbursement would not run so smoothly.

The drug is indicated for: ▲ adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy, and ▲ patients up to 25 years of age with B